Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7019855 | 0.94 | SIGMAR1 (0.57) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL736652 | 0.87 | — | — | |
| SCHEMBL224421 | 0.83 | SIGMAR1 (0.54) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL7449194 | 0.78 | SIGMAR1 (0.57) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL5604 | 0.71 | TSHR (0.48) | ALDH1A1NOS3NOS1NOS2 | |
| 5,6,7,8-Tetrahydroisoquinoline SCHEMBL28211 | 0.70 | SIGMAR1 (1.00) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL2388666 | 0.70 | — | — | |
| SCHEMBL29518090 | 0.70 | — | — | |
| Bromide SCHEMBL11831501 | 0.70 | TSHR (0.46) | ALDH1A1NOS3NOS1NOS2 | |
| SCHEMBL737232 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | claimed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | claimed |
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | claimed |
| CN-118252829-A | CRF receptor antagonists and methods of use | 纽罗克里生物科学有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | BIOND BIOLOGICS LTD. (IL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024091541-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091538-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091542-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-113226310-B | 15-PGDH inhibitors | 杏林制药株式会社 | 2024-03-19 | — | — | CN | disclosed |
| EP-1065204-A1 | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1065206-A1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| US-6133409-A | REACTING A SOLID SUPPORT-BOUND N-ALKYLATED HYDROXAMIC ACID WITH A CARBON-NITROGEN CLEAVING ORGANOMETALLIC COMPUND TO LIBERATE THE PRODUCT KETONE | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6127515-A | Functionalized resin for the synthesis of amides and peptides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-1030665-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999048870-A1 | PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999020275-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | LCAT, CD47, PHOSPHO1 | SIGMAR1 3114/4885CHRNB2 4055/4885CHRNA4 4681/4885 |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | ACTB, CHERP, EEA1 | SIGMAR1 1745/4885CHRNB2 2986/4885CHRNA4 4260/4885 |
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | NR0B1, GRK4, CRKL | SIGMAR1 439/4885CHRNB2 459/4885CHRNA4 205/4885 |
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | SIGMAR1 559/4885CHRNB2 39/4885CHRNA4 112/4885 |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | NR0B1, GRK4, CRKL | SIGMAR1 439/4885CHRNB2 459/4885CHRNA4 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.